NEW YORK (GenomeWeb News) – OriGene Technologies today announced the completion of its $21.3 million Series C financing round.

Qiming Venture Partners and Kleiner Perkins Caufield Byers China led the round, while existing investor IDG-Accel also participated, OriGene said.

The company intends to use the financing to "advance our growth strategy and operations," Wei-Wu He, OriGene's chairman and CEO, said in a statement, without elaborating.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: The sea anemone is sequenced, a team describes a CRISPR/Cas9-based approach to label specific sites in the genome, and more. 

In a short video, CNN introduces viewers to a fecal transplant poop donor and explains how the treatments are made.

Researchers are testing the use of transgenically altered diamondback moths as an alternative to pesticides in controlling the bugs.

Two recent papers published in Science and Nature Medicine describe work that may result in a universal vaccine for the flu.